1887
  1. Home
  2. Eurosurveillance
  3. Volume 26, Issue 24, 17/Jun/2021
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

Residents in long-term care facilities (LTCF) experienced a large morbidity and mortality during the COVID-19 pandemic in Spain and were prioritised for early COVID-19 vaccination. We used the screening method and population-based data sources to obtain estimates of mRNA COVID-19 vaccine effectiveness for elderly LTCF residents. The estimates were 71% (95% CI: 56–82%), 88% (95% CI: 75–95%), and 97% (95% CI: 92-99%), against SARS-CoV-2 infections (symptomatic and asymptomatic), and COVID-19 hospitalisations and deaths, respectively.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.24.2100452
2021-06-17
2024-12-22
/content/10.2807/1560-7917.ES.2021.26.24.2100452
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/24/eurosurv-26-24-5.html?itemId=/content/10.2807/1560-7917.ES.2021.26.24.2100452&mimeType=html&fmt=ahah

References

  1. Instituto de Mayores y Servicios Sociales (IMSERSO). Actualización no 6. Enfermedad por coronavirus (COVID-19) en Centros Residenciales. [Update No. 6. Coronavirus (COVID-19) in Residential Centers]. Madrid: IMERSO; 2021. Spanish. Available from: https://www.imserso.es/InterPresent1/groups/imserso/documents/binario/inf_resid_20210404.pdf
  2. Ministerio de Sanidad, Gobierno de España. Informe de Gestión Integral de la Vacunación COVID-19, Fecha del informe 12 de abril de 2021. [COVID-19 Vaccination Management Report, Ministry of Health, Government of Spain]. Madrid: Ministerio de Sanidad; 2021. Spanish. Available from: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Informe_GIV_comunicacion_20210412.pdf
  3. Farrington CP. Estimation of vaccine effectiveness using the screening method. Int J Epidemiol. 1993;22(4):742-6.  https://doi.org/10.1093/ije/22.4.742  PMID: 8225751 
  4. Remschmidt C, Rieck T, Bödeker B, Wichmann O. Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany. BMC Infect Dis. 2015;15(1):137.  https://doi.org/10.1186/s12879-015-0882-3  PMID: 25887460 
  5. Mazagatos C, Delgado-Sanz C, Oliva J, Gherasim A, Larrauri A, Spanish Influenza Surveillance System. Exploring the risk of severe outcomes and the role of seasonal influenza vaccination in pregnant women hospitalized with confirmed influenza, Spain, 2010/11-2015/16. PLoS One. 2018;13(8):e0200934.  https://doi.org/10.1371/journal.pone.0200934  PMID: 30089148 
  6. Shrotri M, Krutikov M, Palmer T, Giddings R, Azmi B, Subbarao S, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities (VIVALDI study). medRxiv. 2021.03.26.21254391.
  7. Tande AJ, Pollock BD, Shah ND, Farrugia G, Virk A, Swift M, et al. Impact of the COVID-19 vaccine on asymptomatic infection among patients undergoing pre-procedural COVID-19 molecular screening. Clin Infect Dis. 2021;ciab229.  https://doi.org/10.1093/cid/ciab229  PMID: 33704435 
  8. Johansson MA, Quandelacy TM, Kada S, Prasad PV, Steele M, Brooks JT, et al. SARS-CoV-2 transmission from people without COVID-19 symptoms. JAMA Netw Open. 2021;4(1):e2035057.  https://doi.org/10.1001/jamanetworkopen.2020.35057  PMID: 33410879 
  9. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412-23.  https://doi.org/10.1056/NEJMoa2101765  PMID: 33626250 
  10. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819-29.  https://doi.org/10.1016/S0140-6736(21)00947-8  PMID: 33964222 
  11. Tenforde MW, Olson SM, Self WH, Talbot HK, Lindsell CJ, Steingrub JS, et al. Effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 among hospitalized adults aged ≥65 years - United States, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021;70(18):674-9.  https://doi.org/10.15585/mmwr.mm7018e1  PMID: 33956782 
  12. Monge S, Olmedo C, Alejos B, Lapeña MF, Sierra MJ, Limia A, et al. Direct and indirect effectiveness of mRNA vaccination against SARS-CoV-2 infection in long-term care facilities in Spain. medRxiv. 2021.04.08.21255055.
  13. Cabezas C, Coma E, Mora-Fernandez N, Li X, Martinez-Marcos M, Fina-Aviles F, et al. Effects of BNT162b2 mRNA vaccination on COVID-19 disease, hospitalisation and mortality in nursing homes and healthcare workers: a prospective cohort study including 28,594 nursing home residents, 26,238 nursing home staff, and 61,951 healthcare workers in Catalonia. 2021. Available from: https://papers.ssrn.com/abstract=3815682
  14. Martínez-Baz I, Miqueleiz A, Casado I, Navascués A, Trobajo-Sanmartín C, Burgui C, et al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. Euro Surveill. 2021;26(21):2100438.  https://doi.org/10.2807/1560-7917.ES.2021.26.21.2100438  PMID: 34047271 
Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Clara+Mazagatos&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mazagatos Clara</a>, <a href="/search?value1=Susana+Monge&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Monge Susana</a>, <a href="/search?value1=Carmen+Olmedo&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Olmedo Carmen</a>, <a href="/search?value1=Lorena+Vega&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Vega Lorena</a>, <a href="/search?value1=Pilar+Gallego&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Gallego Pilar</a>, <a href="/search?value1=Elisa+Mart%C3%ADn-Merino&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Martín-Merino Elisa</a>, <a href="/search?value1=Mar%C3%ADa+Jos%C3%A9+Sierra&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Sierra María José</a>, <a href="/search?value1=Aurora+Limia&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Limia Aurora</a>, <a href="/search?value1=Amparo+Larrauri&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Larrauri Amparo</a>, <a href="/search?value1=Working+Group+for+the+surveillance+and+control+of+COVID-19+in+Spain&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Working Group for the surveillance and control of COVID-19 in Spain</a></span>. Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021. <a href="/content/ecdc">Euro Surveill.</a> 2021;26(24):pii=2100452. <a href="https://doi.org/10.2807/1560-7917.ES.2021.26.24.2100452" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2021.26.24.2100452</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 20 May 2021;&nbsp;&nbsp; <span class="generated">Accepted</span>: 16 Jun 2021 </span> </p>
/content/10.2807/1560-7917.ES.2021.26.24.2100452
/content/10.2807/1560-7917.ES.2021.26.24.2100452
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error